Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
China's National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one weight-related complication.Danish pharmaceutical company Novo Nordisk A/S (NYSE:NVO) said it will officially launch its weight-loss drug Wegovy in China.
丹麦药品公司诺和诺德（纽交所代码：NVO）表示，将在中国正式推出其减肥药Wegovy。
China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
中国国家卫生健康委员会的调查显示，超过一半的14亿人口超重或肥胖。
Wegovy is the world's first weekly glucagon-like peptide-1 receptor agonist for long-term weight management.
Wegovy是全球首个用于长期体重管理的每周注射的类胰高血糖素肽-1受体激动剂。
China's National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one weight-related complication.
中国国家药品监督管理局（NMPA）在6月底批准了Wegovy。它适用于体重指数（BMI）为30或以上并且至少有一种与体重相关的并发症的个体。
Also Read: Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
另请阅读：Ozempic/Wegovy的maker在需求旺盛的情况下维持第三季度销售增长
Initial sales of Wegovy in China will begin at a public hospital in Shanghai, where the first prescriptions are set to be issued this week, the financial media company Yicai noted.
Wegovy在中国的初始销售将从上海的一家公立医院开始，首批处方预计本周将发放，金融媒体公司第一财经报道。
The cost of a four-injection pack is reported to be around $194 (CNY 1,400) compared to around $1,349 per patient per month in the U.S.
一个四针装的费用报告为约194美元（人民币1400元），而在美国，每位患者每月的费用约为1349美元。
A month's prescription for Wegovy costs $186 in Denmark, $140 in Germany, and $92 in the U.K.
在丹麦，Wegovy一个月的处方费用为186美元，在德国为140美元，在英国为92美元。
In the U.S., Novo Nordisk has been criticized for charging high prices for Wegovy and Ozempic.
在美国，诺和诺德因对Wegovy和Ozempic的高定价而受到批评。
While Novo Nordisk's CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company's blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.
虽然诺和诺德的首席执行官拉尔斯·弗鲁尔加德·约根森为公司畅销药Ozempic和Wegovy的高价格辩护，称这些药物减轻了与肥胖相关的健康问题所带来的经济负担。
Due to the tight supply, access to the medication will be somewhat limited initially, requiring patients to schedule outpatient appointments and undergo a medication assessment.
由于供应紧张，初期药物的获取将受到一定限制，患者需预约门诊并进行药物评估。
Currently, Wegovy is not included in China's national medical insurance program.
目前，Wegovy尚未纳入中国的国家医疗保险计划。
Zhou Xiaping, Novo Nordisk's global senior vice president and president for China, noted that the company is actively pursuing strategies to make the drug more affordable, including potential partnerships with commercial insurance providers.
诺和诺德的全球高级副总裁兼中国区总裁周晓平指出，公司正在积极寻求策略，以使该药物更加负担得起，包括与商业保险提供商的潜在合作。
The Bloomberg report adds that while many patients in the U.S. and Europe get some help with drug costs through insurance, most Chinese consumers will need to pay for the drug themselves.
彭博社的报告补充称，尽管许多美国和欧洲的患者通过保险获得药物费用的帮助，但大多数中国消费者需要自行支付药物费用。
Price Action: NVO stock is down 1.67% at $100.04 at the last check on Monday.
价格走势：NVO股票在周一最后一次检查时下跌1.67%，报100.04美元。
- Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
- 礼来公司的Zepbound/Mounjaro在与肥胖相关的心力衰竭患者中显示出心血管益处
Photo by Tobias Arhelger via Shutterstock
图片由shutterstock提供
